Taiwan · Delayed Price · Currency is TWD Excelsior Biopharma Statistics
Total Valuation
TPEX:6496 has a market cap or net worth of TWD 1.16 billion. The enterprise value is 1.54 billion.
| Market Cap | 1.16B |
| Enterprise Value | 1.54B |
Important Dates
The next estimated earnings date is Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6496 has 46.58 million shares outstanding. The number of shares has increased by 0.40% in one year.
| Current Share Class | 46.58M |
| Shares Outstanding | 46.58M |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 32.00% |
| Owned by Institutions (%) | n/a |
| Float | 16.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.24 |
| PB Ratio | 1.68 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.55 |
| Quick Ratio | 0.75 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.23 |
| Interest Coverage | -22.18 |
Financial Efficiency
Return on equity (ROE) is -26.05% and return on invested capital (ROIC) is -18.26%.
| Return on Equity (ROE) | -26.05% |
| Return on Assets (ROA) | -8.80% |
| Return on Invested Capital (ROIC) | -18.26% |
| Return on Capital Employed (ROCE) | -20.56% |
| Weighted Average Cost of Capital (WACC) | 2.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, TPEX:6496 has paid 11.71 million in taxes.
| Income Tax | 11.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.50% in the last 52 weeks. The beta is -0.17, so TPEX:6496's price volatility has been lower than the market average.
| Beta (5Y) | -0.17 |
| 52-Week Price Change | -11.50% |
| 50-Day Moving Average | 24.64 |
| 200-Day Moving Average | 26.69 |
| Relative Strength Index (RSI) | 55.38 |
| Average Volume (20 Days) | 9,078 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6496 had revenue of TWD 936.92 million and -206.58 million in losses. Loss per share was -4.46.
| Revenue | 936.92M |
| Gross Profit | 361.23M |
| Operating Income | -199.67M |
| Pretax Income | -194.87M |
| Net Income | -206.58M |
| EBITDA | -182.21M |
| EBIT | -199.67M |
| Loss Per Share | -4.46 |
Balance Sheet
The company has 141.10 million in cash and 524.98 million in debt, with a net cash position of -383.88 million or -8.24 per share.
| Cash & Cash Equivalents | 141.10M |
| Total Debt | 524.98M |
| Net Cash | -383.88M |
| Net Cash Per Share | -8.24 |
| Equity (Book Value) | 688.99M |
| Book Value Per Share | 14.87 |
| Working Capital | 247.12M |
Cash Flow
In the last 12 months, operating cash flow was -147.79 million and capital expenditures -14.60 million, giving a free cash flow of -162.38 million.
| Operating Cash Flow | -147.79M |
| Capital Expenditures | -14.60M |
| Depreciation & Amortization | 17.45M |
| Net Borrowing | 148.60M |
| Free Cash Flow | -162.38M |
| FCF Per Share | -3.49 |
Margins
Gross margin is 38.56%, with operating and profit margins of -21.31% and -22.05%.
| Gross Margin | 38.56% |
| Operating Margin | -21.31% |
| Pretax Margin | -20.80% |
| Profit Margin | -22.05% |
| EBITDA Margin | -19.45% |
| EBIT Margin | -21.31% |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6496 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | -0.40% |
| Earnings Yield | -17.81% |
| FCF Yield | -14.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |